 4. Patients must have either low risk or low-tier intermediate risk prostate cancer Low risk must have all of: clinical stage T2b, Gleason score 6, and initial PSA 10; Low-tier intermediate risk must have: clinical stage T2c, 50 positive biopsy cores, AND EITHER Gleason score 7 and initial PSA 10 OR Gleason score 6 and initial PSA 10 and 15. 